A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF PF-07817883 FOLLOWING ORAL ADMINISTRATION OF NEW FORMULATIONS RELATIVE TO THE REFERENCE FORMULATION IN HEALTHY ADULT PARTICIPANTS UNDER FASTED CONDITION
Latest Information Update: 05 Feb 2025
At a glance
- Drugs Ibuzatrelvir (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 01 Feb 2024 Status changed from active, no longer recruiting to completed.
- 18 Dec 2023 Planned End Date changed from 11 Jan 2024 to 8 Jan 2024.
- 18 Dec 2023 Planned primary completion date changed from 11 Jan 2024 to 8 Jan 2024.